The American pharmaceutical company Johnson & Johnson has filed an application for registration of its one-component coronavirus vaccine.
The next step in the process is a meeting of the Food and Drug Administration (FDA) advisory group, during which vaccine experts will review the research findings.
The meeting could take place in two weeks.
The company said in a statement that it expects to begin deliveries as soon as the permit is received, but did not specify the estimated volume of deliveries.
The company still expects to deliver on its promise to deliver 100 million doses by mid-year.
Johnson & Johnson’s head of research, Paul Stoffels, said the company is “working hard” to make its experimental vaccine available to the public as soon as possible.
Unlike the two-dose vaccines developed by Pfizer and Moderna, Johnson & Johnson’s vaccine has only one component, so it will be easier to distribute.